LONDON, April 17, 2026 /PRNewswire/ -- iFOREX today announced its recent admission to the Main Market of the London Stock…
ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease…
TAIPEI, March 11, 2026 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, introduces the Z890 Plus Series Motherboards engineered to…
PROVIDENCIALES, Turks and Caicos Islands, March 2, 2026 /PRNewswire/ -- KuCoin, a leading global crypto platform built on trust, today announced…
MÖNCHENGLADBACH, Germany, Dec. 18, 2025 /PRNewswire/ -- As 2025 draws to a close, Tradewind Finance, an international trade finance provider, is…
DUBAI, UAE, Dec. 17, 2025 /PRNewswire/ -- On the evening of December 14 local time, fireworks illuminated the Dubai night sky, casting…
All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial…
November 27, 2025 09:30 ET | Source: GS1 Canada TORONTO, Nov. 27, 2025 (GLOBE NEWSWIRE) -- A new report prepared…
13 November 2025 - Building on the momentum of the Olympic AI Agenda launched in April 2024, the International Olympic Committee (IOC) held…
New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its…